Chemotherapy-resistant urothelial carcinoma has no uniformly curative therapy. Understanding how selective pressure from chemotherapy directs the evolution of urothelial carcinoma and shapes its clonal architecture is a central biological question with clinical implications. To address this question, we performed whole-exome sequencing and clonality analysis of 72 urothelial carcinoma samples, including 16 matched sets of primary and advanced tumors prospectively collected before and after chemotherapy. Our analysis provided several insights: (i) chemotherapy-treated urothelial carcinoma is characterized by intra-patient mutational heterogeneity, and the majority of mutations are not shared; (ii) both branching evolution and metastatic spread are very early events in the natural history of urothelial carcinoma; (iii) chemotherapy-treated urothelial carcinoma is enriched with clonal mutations involving L1 cell adhesion molecule (L1CAM) and integrin signaling pathways; and (iv) APOBEC-induced mutagenesis is clonally enriched in chemotherapy-treated urothelial carcinoma and continues to shape the evolution of urothelial carcinoma throughout its lifetime.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. SEER Cancer Statistics Review, 1975–2010 (National Cancer Institute, Bethesda, Maryland, USA, 2013).

  2. 2.

    et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602–4608 (2005).

  3. 3.

    et al. Bladder cancer. J. Natl. Compr. Canc. Netw. 11, 446–475 (2013).

  4. 4.

    et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol. 19, 2638–2646 (2001).

  5. 5.

    et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer 42, 50–54 (2006).

  6. 6.

    et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 27, 4454–4461 (2009).

  7. 7.

    & New therapeutic challenges in advanced bladder cancer. Semin. Oncol. 39, 598–607 (2012).

  8. 8.

    Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014).

  9. 9.

    et al. Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol. 15, 439 (2014).

  10. 10.

    The parsimony ratchet, a new method for rapid parsimony analysis. Cladistics 15, 407–414 (1999).

  11. 11.

    et al. Identification of Pold2 as a novel interaction partner of protein inhibitor of activated STAT2. Int. J. Mol. Med. 30, 884–888 (2012).

  12. 12.

    , & Human Pol ζ purified with accessory subunits is active in translesion DNA synthesis and complements Pol η in cisplatin bypass. Proc. Natl. Acad. Sci. USA 111, 2954–2959 (2014).

  13. 13.

    et al. FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis. Cell Death Differ. 20, 1219–1229 (2013).

  14. 14.

    et al. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells. Oncotarget 7, 3506–3519 (2016).

  15. 15.

    et al. E-cadherin/p120-catenin and tetraspanin Co-029 cooperate for cell motility control in human colon carcinoma. Cancer Res. 70, 7674–7683 (2010).

  16. 16.

    , & TSPAN8 promotes gastric cancer growth and metastasis via ERK MAPK pathway. Int. J. Clin. Exp. Med. 8, 8599–8607 (2015).

  17. 17.

    Tetraspanins: push and pull in suppressing and promoting metastasis. Nat. Rev. Cancer 9, 40–55 (2009).

  18. 18.

    et al. Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database (Oxford) 2011, bar030 (2011).

  19. 19.

    et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur. Urol. 68, 959–967 (2015).

  20. 20.

    & Focal adhesion signaling and therapy resistance in cancer. Semin. Cancer Biol. 31, 65–75 (2015).

  21. 21.

    & Cisplatin at sub-toxic levels mediates integrin switch in lung cancer cells. Anticancer Res. 34, 7111–7117 (2014).

  22. 22.

    , , & Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 25, 234–240 (2015).

  23. 23.

    et al. L1 cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma. J. Surg. Oncol. 103, 669–673 (2011).

  24. 24.

    , & L1-CAM as a target for treatment of cancer with monoclonal antibodies. Anticancer Res. 29, 4919–4931 (2009).

  25. 25.

    et al. C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency. Genome Res. 24, 1624–1636 (2014).

  26. 26.

    et al. A comprehensive survey of the mutagenic impact of common cancer cytotoxics. Genome Biol. 17, 99 (2016).

  27. 27.

    et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).

  28. 28.

    et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979–993 (2012).

  29. 29.

    et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat. Genet. 48, 600–606 (2016).

  30. 30.

    et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970–976 (2013).

  31. 31.

    et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol. 2, 1094–1096 (2016).

  32. 32.

    et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4, 1140–1153 (2014).

  33. 33.

    et al. APOBEC3A and APOBEC3B preferentially deaminate the lagging strand template during DNA replication. Cell Rep. 14, 1273–1282 (2016).

  34. 34.

    et al. APOBEC3B and AID have similar nuclear import mechanisms. J. Mol. Biol. 419, 301–314 (2012).

  35. 35.

    , & Stochastic properties of processive cytidine DNA deaminases AID and APOBEC3G. Phil. Trans. R. Soc. Lond. B 364, 583–593 (2009).

  36. 36.

    & Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 4, 868–877 (2004).

  37. 37.

    , , & Novel molecular targets for urothelial carcinoma. Expert Opin. Ther. Targets 19, 515–525 (2015).

  38. 38.

    & Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 15, 25–41 (2015).

  39. 39.

    et al. L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells. Cancer Lett. 316, 70–76 (2012).

  40. 40.

    et al. L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol. Oncol. 104, 461–469 (2007).

  41. 41.

    et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 26, 2759–2768 (2007).

  42. 42.

    et al. alpha5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma. Int. J. Oncol. 34, 243–253 (2009).

  43. 43.

    et al. L1CAM: a major driver for tumor cell invasion and motility. Cell Adh. Migr. 6, 374–384 (2012).

  44. 44.

    et al. The RGD integrin binding site in human L1-CAM is important for nuclear signaling. Exp. Cell Res. 314, 2411–2418 (2008).

  45. 45.

    , , & Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol. Biol. Cell 12, 2699–2710 (2001).

  46. 46.

    et al. Direct contact with perivascular tumor cells enhances integrin αvβ3 signaling and migration of endothelial cells. Oncotarget (2016).

  47. 47.

    et al. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ. 13, 1776–1788 (2006).

  48. 48.

    et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 5, 662–668 (1999).

  49. 49.

    et al. Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway. Cancer 95, 896–906 (2002).

  50. 50.

    et al. The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Virology 367, 440–451 (2007).

  51. 51.

    & Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol. Cancer Ther. 1, 69–78 (2001).

  52. 52.

    Integrins as novel drug targets for overcoming innate drug resistance. Curr. Cancer Drug Targets 2, 37–43 (2002).

  53. 53.

    & Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev. 20, 43–50 (2001).

  54. 54.

    , & Signalling via integrins: implications for cell survival and anticancer strategies. Biochim. Biophys. Acta 1775, 163–180 (2007).

  55. 55.

    et al. Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM. MAbs 8, 414–425 (2016).

  56. 56.

    et al. L1 cell adhesion molecule is a novel therapeutic target in intrahepatic cholangiocarcinoma. Clin. Cancer Res. 16, 3571–3580 (2010).

  57. 57.

    et al. Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. Cancer Lett. 319, 66–82 (2012).

  58. 58.

    Targeting FAK in human cancer: from finding to first clinical trials. Front. Biosci. (Landmark Ed.) 19, 687–706 (2014).

  59. 59.

    & Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin. Investig. Drugs 19, 777–788 (2010).

  60. 60.

    , & Cisplatin enhances the formation of DNA single- and double-strand breaks by hydrated electrons and hydroxyl radicals. Radiat. Res. 179, 323–331 (2013).

  61. 61.

    et al. Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells. J. Cell Biol. 208, 563–579 (2015).

  62. 62.

    & Hypermutation in human cancer genomes: footprints and mechanisms. Nat. Rev. Cancer 14, 786–800 (2014).

  63. 63.

    et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat. Genet. 47, 1067–1072 (2015).

  64. 64.

    et al. Cancer evolution and the limits of predictability in precision cancer medicine. Trends Cancer 2, 49–63 (2016).

  65. 65.

    et al. Whole-exome sequencing of metastatic cancer and iomarkers of treatment response. JAMA Oncol. 1, 466–474 (2015).

  66. 66.

    et al. SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Res. 36, 2446–2456 (2008).

  67. 67.

    et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298–305 (2016).

  68. 68.

    et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177–183 (2004).

  69. 69.

    et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27, 382–396 (2015).

  70. 70.

    et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).

  71. 71.

    , , , & Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma. PLoS One 7, e40332 (2012).

  72. 72.

    , , , & ASEQ: fast allele-specific studies from next-generation sequencing data. BMC Med. Genomics 8, 9 (2015).

  73. 73.

    et al. Oncotator: cancer variant annotation tool. Hum. Mutat. 36, E2423–E2429 (2015).

  74. 74.

    et al. The sequence ontology: a tool for the unification of genome annotations. Genome Biol. 6, R44 (2005).

Download references


We would like to thank our patients and their families for participation in this study. We would like to thank B. Sleckman for constructive review of the manuscript. We would also like to acknowledge D. Scherr and C. Barbieri for contributing samples, our research and clinical pathology fellows J. Fontugne, M. Kossai, C. Pauli, K. Hennrick and K. Park for their assistance during rapid autopsies, and S.S. Chae and D. Wilkes for technical assistance and constructive comments. We would also like to thank T.Y. MacDonald, J. Padilla and T. Fedrizzi for technical assistance. Work was partially supported by the Translational Research Program at WCMC Pathology and Laboratory Medicine. This work was supported by a Conquer Cancer Foundation and the John and Elizabeth Leonard Family Foundation Young Investigator Award (B.M.F.), NIH/NCATS KL2TR000458 (B.M.F.), Early Detection Research Network US NCI 5U01 CA111275-09 (J.M.M., M.A.R. and F.D.), Damon Runyon Cancer Research Foundation Clinical Investigator Award CI-67-13 (H.B.), and H2020 European Research Council ERC-CoG 648670 (F.D.).

Author information

Author notes

    • Bishoy M Faltas
    •  & Davide Prandi

    These authors contributed equally to this work.

    • Himisha Beltran
    • , Francesca Demichelis
    •  & Mark A Rubin

    These authors jointly directed this work.


  1. Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital–Weill Cornell Medicine, New York, New York, USA.

    • Bishoy M Faltas
    • , Scott T Tagawa
    • , Ana M Molina
    • , David M Nanus
    • , Juan Miguel Mosquera
    • , Brian Robinson
    • , Olivier Elemento
    • , Andrea Sboner
    • , Himisha Beltran
    • , Francesca Demichelis
    •  & Mark A Rubin
  2. Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA.

    • Bishoy M Faltas
    • , Scott T Tagawa
    • , Ana M Molina
    • , David M Nanus
    •  & Himisha Beltran
  3. Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, New York, USA.

    • Bishoy M Faltas
    • , Scott T Tagawa
    • , David M Nanus
    • , Himisha Beltran
    •  & Mark A Rubin
  4. Centre for Integrative Biology, University of Trento, Trento, Italy.

    • Davide Prandi
    •  & Francesca Demichelis
  5. Department of Medical Oncology, San Camillo–Forlanini Hospital, Rome, Italy.

    • Cora Sternberg
  6. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

    • Jonathan Rosenberg
  7. Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.

    • Juan Miguel Mosquera
    • , Brian Robinson
    • , Andrea Sboner
    •  & Mark A Rubin
  8. Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York, USA.

    • Olivier Elemento
  9. Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York, USA.

    • Olivier Elemento
    • , Andrea Sboner
    •  & Francesca Demichelis


  1. Search for Bishoy M Faltas in:

  2. Search for Davide Prandi in:

  3. Search for Scott T Tagawa in:

  4. Search for Ana M Molina in:

  5. Search for David M Nanus in:

  6. Search for Cora Sternberg in:

  7. Search for Jonathan Rosenberg in:

  8. Search for Juan Miguel Mosquera in:

  9. Search for Brian Robinson in:

  10. Search for Olivier Elemento in:

  11. Search for Andrea Sboner in:

  12. Search for Himisha Beltran in:

  13. Search for Francesca Demichelis in:

  14. Search for Mark A Rubin in:


Initiation and design of study: B.M.F., H.B., M.A.R. and F.D. Subject enrollment and sample and clinical data collection: B.M.F., H.B., D.M.N., S.T.T., A.M.M., C.S., J.M.M. and B.R. Statistical and bioinformatics analyses: D.P., O.E., A.S. and F.D. Supervision of research: B.M.F., M.A.R., J.R. and F.D. Writing of the first draft of the manuscript: B.M.F., D.P., H.B., M.A.R. and F.D. All authors contributed to the writing and editing of the revised manuscript and approved the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Francesca Demichelis or Mark A Rubin.

Integrated supplementary information

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–14 and Supplementary Note

Excel files

  1. 1.

    Supplementary Tables 1–11

    Supplementary Tables 1–11

About this article

Publication history






Further reading